HELP WITH HEALTHCARE

New app gives good shot at finding COVID-19 vaccination in Houston

This new guide helps streamline vaccine sites and eligibility information in one place. Photo courtesy of CVS Health

Are you frustrated by the hoops you're jumping through to get a COVID-19 vaccination? The GoodRx drug-price-comparison app has stepped in to help.

GoodRx just rolled out a guide so you can learn about the COVID-19 vaccine, track its availability, and set up a vaccination appointment in Houston or elsewhere in Texas.

"Vaccine information has been fragmented and availability unclear, so GoodRx has built the go-to destination for all Americans to track the vaccine rollout locally," the company says in a statement.

GoodRx is collecting data from more than 15,000 vaccination sites and is monitoring the country's 70,000 pharmacies as well as state-specific sites to update appointment availability. New information is added as it becomes available.

Among other things, the GoodRx guide tells you who's eligible for vaccinations where you live, who's next in line, and how you can make a vaccination appointment. You can even sign up to receive text messages that alert you when vaccination eligibility changes in your area.

This news comes as Texas Gov. Greg Abbott has reopened the state and lifted the mask mandate — which could put Houstonians at even greater risk.

Meanwhile, throughout Texas, the recent winter storm, power outages, and water shortages hampered the ability to distribute COVID-19 vaccines. As of March 3, Harris County shows some 351,063 confirmed COVD cases, according to most-recent data, and 2,297,878 cases statewide. Information about the Texas vaccination plan is available on the Department of State Health Services website.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News